New structure and operating model 'will prepare EMA for future challenges'
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has published details of its new organizational structure, which it says will allow it to focus on its key tasks and support its role in the EU drug regulatory system. Among the key changes are four new core divisions, improved co-ordination with stakeholders, and the addition of two major advisory functions on policy and program design.